Improving public health through collaboration in research

International Congress Series

Volumn 1267, Issue C, 2004, Pages 7-16

  Bergquist, N Robert ^a  

^a NONE   (Sweden)

Author keywords

Disease control; Pharmacological industry; Public health; Research; Tropical disease

Indexed keywords

EID: 13944261450     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.01.077     Document Type: Article

References (21)

1. P.A. Singer A.S. Daar Harnessing genomics and biotechnology to improve global health equity Science 294 5550 2001 2289 2290
2. A.S. Daar H. Thorsteinsdottir D.K. Martin A.C. Smith S. Nast P.A. Singer Top ten biotechnologies for improving health in developing countries Nat. Genet. 32 2 2002 229 232
3. J. Sachs The essential ingredient New Sci. 175 2002 52 55
4. D.A. Henderson Eradication: lessons from the past Bull. World Health Organ. 76 2 1998 17 21
5. D.H. Molyneux C. Morel Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios Br. Med. Bull. 54 2 1998 327 339
6. C.M. Morel Neglected diseases: under-funded research and inadequate health interventions. Can we change this reality? EMBO Rep. 4 2003 35 38
7. Global Forum for Health Research, The10/90 Report on Health Research 2001–2002 Global Forum for Health Research (2000). Geneva, Switzerland.
8. B. Pecoul M. Gastellu Production of sleeping-sickness treatment Lancet 354 9182 1999 955 956
9. S. Nwaka R.G. Ridley Virtual drug discovery and development for neglected diseases through public–private partnerships Nat. Rev., Drug Discov. 2 11 2003 919 928
10. R.G. Ridley Product R&D for neglected diseases EMBO Rep. 4 2003 43 46
11. T. Lang B. Greenwood The development of Lapdap, an affordable new treatment for malaria Lancet, Infect. Dis. 3 3 2003 162 168
12. R.G. Ridley Chemotherapeutic hope on the horizon for Plasmodium vivax malaria? Proc. Natl. Acad. Sci. U. S. A. 99 21 2002 13362 13364
13. D.J. Chen L.F. Fu P.P. Shao F.Z. Wu C.Z. Fan H. Shu C.S. Ren X.L. Sheng Effect of artemisinin on experimental animals infected with Schistosoma japonicum Chin Med. J. (Chinese) 80 1980 422 425
14. J. Utzinger S. Xiao E.K. N'Goran R. Bergquist M. Tanner The potential of artemether for the control of schistosomiasis (review) Int. J. Parasitol. 31 2001 1549 1562
15. J. Utzinger E.K. N'Goran A. N'Dri C. Lengeler S.H. Xiao M. Tanner Oral artemether for prevention of Schistosoma mansoni : randomized controlled trial Lancet 355 2000 1325 1329
16. E.K. N'Goran J. Utzinger H.N. Gnaka A. Yapi N.A. N'Guessan S.D. Kigbafori C.J. Chollet X. Shuhua Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections Am. J. Trop. Med. Hyg. 68 1 2003 24 32
17. S. Sundar T.K. Jha C.P. Thakur J. Engel H. Sindermann C. Fischer K. Junge A. Bryceson J. Berman Oral miltefosine for Indian visceral leishmaniasis N. Engl. J. Med. 347 22 2002 1739 1746
18. S. Bhattacharya Capacity building for clinical trials: the investigator's perspective TDR News 69 2002 (November)
19. A.L. de Andrade F. Zicker R.M. de Oliveira S. Almeida Silva A. Luquetti L.R. Travassos I.C. Almeida S.S. de Andrade J.G. de Andrade C.M. Martelli Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection Lancet 348 9039 1996 1407 1413
20. C.M. Morel Chagas disease, from discovery to control- and beyond: history, myths and lessons to take home Mem. Inst. Oswaldo Cruz 94 1 1999 3 16
21. Health sector reform and social, economic and behavioural research. In: Sixteenth Programme Report. Progress 2001–2002, pp. 19–21 (document number TDR/GEN/03.1) 2003.